uniQure (QURE)
(Delayed Data from NSDQ)
$4.91 USD
+0.03 (0.61%)
Updated May 14, 2024 04:00 PM ET
After-Market: $4.91 0.00 (0.00%) 6:50 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Brokerage Reports
0 items in cart
uniQure N.V. [QURE]
Reports for Purchase
Showing records 141 - 153 ( 153 total )
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
Positive Regulatory Development on Glybera should Alleviate Concerns
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
We Would be Buyers on any Weakness Caused by Competitor Failure
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
Disrupting Lysosomal-Storage Disorder Franchises With Gene Therapy
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
Healthcare -Catalyst-Driven Visibility Boost for Gene Therapy Sector
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
Corlanor (Amgen) Approval Spotlights Opportunities in Heart Failure
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
We initiate coverage of uniQure with a Buy rating and $38 target
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
4Q14 Update: Exclusive Agreement with Bristol-Meyers Squibb on CVD; Raising PT
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: LIN C
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
Fixing the Code-The Next Chapter in Medicine; Initiate with a Buy Rating and $30 PT
Provider: H.C. WAINWRIGHT & CO., INC.